INMD — InMode Ltd.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Chart, dilution, float and news for INMD in the TickerWise workspace.

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

Company profile

• Sector: Healthcare
• Industry: Medical - Devices
• Country: IL
• Exchange: NASDAQ
• Employees: 599
• Website: https://www.inmodemd.com

Latest SEC filings for INMD

• 2026-09-166-K
• 2026-08-056-K
• 2026-08-036-K
• 2026-07-206-K
• 2026-07-136-K
• 2026-07-106-K
• 2026-06-256-K
• 2026-06-246-K
• 2026-06-186-K
• 2026-05-206-K

Latest INMD news

• 2026-10-13InMode expects Q3 revenue between $91.8M and $92M Read article
• 2026-10-13InMode to Report Third Quarter 2026 Financial Results on November 11, 2026, Expects Third Quarter Revenue of $91.8 Million to $92.0 Million, Reiterates FY 2026 Revenue Guidance Between $365M-$375M Read article
• 2026-09-25InMode: Hope Is Not An Effective Investment Strategy, But Neither Is Despair Read article

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Educational tool only — not investment advice.